Navigation Links
PEG-Liposome siRNA In Vivo Transfection Kit From Altogen Biosystems
Date:10/21/2010

LAS VEGAS, Oct. 21 /PRNewswire/ -- Altogen Biosystems announced the release of its second generation of in vivo RNAi transfection reagent (http://www.altogen.com/mirna.php) in the company's popular in vivo delivery product line: PEG-Liposome siRNA In Vivo Transfection Kit. This reagent is also compatible for in vivo transfection of other negatively charged molecules – RNA, DNA, and small proteins. The company also offers custom encapsulation of target molecules into PEG-liposome in vivo transfection reagent.

Transfection is one of the major laboratory methods used to introduce DNA and RNA molecules into cells and tissues. This technique makes it possible to cross the cellular barriers and deliver a gene or a small interfering RNA (siRNA) into the cells for research or therapeutic purposes.

Novel PEGylated liposome-based siRNA delivery kit is optimized for directed RNAi induction by efficient delivery of functional small RNA molecules (siRNA, shRNA, miRNA) into tissues. Liposome component provides in vivo siRNA protection due to efficient siRNA-liposome encapsulation. A remarkable feature of this reagent is reduced innate immune response and low cytotoxicity due to biodegradable PEG modification.  

Altogen Biosystems (www.altogen.com) has previously developed nanoparticle-, polymer- and lipid-based in vivo transfection systems (www.altogen.com/mirna.htm) used for laboratory testing pharmaceuticals in cells and animals.

Altogen Biosystems is focusing on commercializing pharma- and bio-technologies, as well as providing custom laboratory services. The company offers pre-clinical contract research services (CRO) including Pharmacology/Toxicology studies, assay development, molecular and cell biology services, development of stable cell lines, gene silencing and complete RNAi services (www.altogenservices.com).

Link: Altogen In Vivo Transfection Reagents: http://www.altogen.com/mirna.php


'/>"/>
SOURCE Altogen Biosystems
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
2. Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
3. Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models
4. Intradigm Receives Notice of Allowance for Key RNA Interference (RNAi) Patent Covering Potent siRNA Sequence
5. PCI Biotech-led Consortium Awarded EUR1.1 m Eurostars Grant for siRNA
6. Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening
7. Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics
8. Sirnaomics Receives Two SBIR Grants from NIH for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection
9. Access Pharmaceuticals Furthers Progress on Its Cobalamin-mediated Targeted Drug Delivery Platform for siRNA
10. MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting
11. The MaxCyte STX Scalable Transfection System to be Launched at the SBS Symposium on Cell-Based Assays
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... by its major shareholders, Clean Technology Fund I, LP ... States based venture capital funds which together ... (on a fully diluted, as converted basis), that they ... their entire equity holdings in Biorem to TUS Holdings ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
Breaking Biology Technology:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/9/2016)... 9, 2016 Paris Police ... video security solution to ensure the safety of people and ... during the major tournament Teleste, an international technology ... services, announced today that its video security solution will be ... back up public safety across the country. The system roll-out ...
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
Breaking Biology News(10 mins):